Zacks Investment Research Upgrades Zosano Pharma (NASDAQ:ZSAN) to Hold

Zosano Pharma (NASDAQ:ZSAN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports.

According to Zacks, “Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company’s lead product candidates include Weekly ZP-PTH for severe osteoporosis; ZP-Glucagon for severe hypoglycemia and ZP-Triptan, for migraine. Zosano Pharma Corporation is headquartered in Fremont, California. “

A number of other research analysts have also recently issued reports on ZSAN. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Zosano Pharma in a report on Monday, June 15th. ValuEngine raised Zosano Pharma from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Maxim Group reaffirmed a “buy” rating on shares of Zosano Pharma in a report on Wednesday, May 20th. Finally, BTIG Research cut their price target on Zosano Pharma from $16.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 27th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $4.00.

Shares of NASDAQ ZSAN traded down $0.03 during midday trading on Friday, reaching $0.81. 966,862 shares of the company traded hands, compared to its average volume of 1,415,590. The firm has a market cap of $45.55 million, a PE ratio of -0.45 and a beta of 2.73. The stock’s 50-day simple moving average is $0.90 and its 200-day simple moving average is $0.96. Zosano Pharma has a 12 month low of $0.41 and a 12 month high of $3.54. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.93 and a current ratio of 0.93.

Zosano Pharma (NASDAQ:ZSAN) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.04. On average, equities research analysts expect that Zosano Pharma will post -0.5 EPS for the current year.

A number of large investors have recently made changes to their positions in ZSAN. Ieq Capital LLC bought a new stake in Zosano Pharma during the 4th quarter worth about $79,000. Oxford Asset Management LLP acquired a new position in shares of Zosano Pharma during the 4th quarter worth about $57,000. Banco Bilbao Vizcaya Argentaria S.A. acquired a new position in shares of Zosano Pharma during the 4th quarter worth about $182,000. UBS Group AG grew its position in shares of Zosano Pharma by 93.1% during the 4th quarter. UBS Group AG now owns 68,557 shares of the biotechnology company’s stock worth $105,000 after buying an additional 33,057 shares during the period. Finally, BlackRock Inc. grew its position in shares of Zosano Pharma by 6.8% during the 1st quarter. BlackRock Inc. now owns 385,675 shares of the biotechnology company’s stock worth $216,000 after buying an additional 24,431 shares during the period. 17.05% of the stock is owned by hedge funds and other institutional investors.

About Zosano Pharma

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.

Further Reading: Insider Trading

Get a free copy of the Zacks research report on Zosano Pharma (ZSAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.